JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB274925

Human ATP13A2 knockout HEK-293 cell line

Be the first to review this product! 리뷰 제출

|

(0 출판물)

ATP13A2 KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control available. Knockout achieved by CRISPR/Cas9 X = 1 bp insertion Frameshift: 99%. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 이미지
Next Generation Sequencing - Human ATP13A2 knockout HEK-293 cell line (AB274925)
  • NGS

Supplier Data

Next Generation Sequencing - Human ATP13A2 knockout HEK-293 cell line (AB274925)

1 bp deletion after Ser216 of the WT protein

Next Generation Sequencing - Human ATP13A2 knockout HEK-293 cell line (AB274925)
  • NGS

Supplier Data

Next Generation Sequencing - Human ATP13A2 knockout HEK-293 cell line (AB274925)

Knockout achieved by CRISPR/Cas9; X = 1 bp insertion; Frameshift : 99%

주요 정보

세포 유형

HEK-293

Species or organism

Human

조직

Kidney

제형

Liquid

form

Knockout 검증

Next Generation Sequencing

Mutation 정보

Knockout achieved by CRISPR/Cas9 X = 1 bp insertion Frameshift: 99%

Reactivity 정보

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "NGS": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

제품 세부 정보

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

제품 구성

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab274925-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab259776 Human wild-type HEK-293 cell line", "number":"AB274925-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab274925 Human ATP13A2 knockout HEK-293 cell line", "number":"AB274925-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab274925-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab274925 Human ATP13A2 knockout HEK-293 cell line", "number":"AB274925-CMP01", "productcode":"" } ] } } }

특성 및 보관 정보

유전자명
ATP13A2
유전자 편집 종류
Knockout
유전자 편집 방식
CRISPR technology
Knockout 검증
Next Generation Sequencing
품질 관리 - STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX
배송 시 보관 조건
Dry Ice
적절한 단기 보관 조건
-196°C
적절한 장기 보관 조건
-196°C

추가 정보

This supplementary information is collated from multiple sources and compiled automatically.

ATP13A2 also known as PARK9 is a lysosomal P5-type ATPase with a molecular mass of approximately 163 kDa. It functions primarily as a cation transporter involved in the transport of divalent metal ions such as manganese and zinc across lysosomal membranes. The ATP13A2 protein is expressed in various tissues with high levels noted in the brain particularly within the neurons of the substantia nigra. The presence of ATP13A2 is also confirmed in kidney tissues and immune cells indicating a wide tissue distribution.
Biological function summary

ATP13A2 plays a significant role in maintaining metal ion homeostasis inside cells. It is an essential component of the complex regulatory system that ensures proper lysosomal function. The protein impacts autophagy by influencing lysosomal biogenesis and integrity. Furthermore its function in metal ion transport and detoxification suggests a protective role for neurons against metal-induced oxidative stress.

Pathways

ATP13A2 is an important participant in the lysosomal degradation pathway and the autophagy-lysosome pathway. It interacts with proteins such as alpha-synuclein known for its role in neurodegenerative diseases and cellular stress responses. In the context of metal ion homeostasis ATP13A2 operates alongside other transporters and enzymes to maintain cellular ion balance and prevent toxicity.

ATP13A2 mutations associate strongly with neurodegenerative conditions like Parkinson's disease (PD) and Kufor-Rakeb syndrome a rare juvenile-onset parkinsonism. Disruption in ATP13A2 activity leads to cellular dysfunction and neurodegeneration due to impaired lysosomal degradation and metal ion imbalance. It is connected to PARK7 (DJ-1) another protein linked to the pathogenesis of PD suggesting shared pathways or compensatory mechanisms between these proteins in neuronal survival and pathology.

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

초기 취급 지침

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability. <p>1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.<br>2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.<br>3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.<br>4. Incubate the culture at 37°C incubator with 5% CO<sub>2</sub>. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.<br>5. Once confluent passage into an appropriate flask at a density of 2x10<sup>4</sup> cells/cm<sup>2</sup>. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.</p>

Subculture 가이드라인
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
배양 배지

DMEM (High Glucose) + 10% FBS

동결보존 배지

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

제품 프로토콜

타겟 정보

See full target information ATP13A2

대체 명칭 보기

PARK9, Polyamine-transporting ATPase 13A2, ATP13A2

Product promise

저희는 고품질 시약으로 고객님의 연구를 서포트하고자 최선을 다하고 있으며, 모든 단계에서 함께 하겠습니다. 만약 제품이 기대한 성능을 보이지 않을 경우에도 Product Promise로 보호받으실 수 있습니다.
자세한 내용은 이용 약관을 확인해 주세요.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com